- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Medicare Advisory Panel Advises Against Annual Low-dose CT Screen
An advisory panel to the CMS voted against recommending an annual low-dose CT scan for high-risk individuals citing no benefit over the harm of false-positives.
Annual low-dose CT lung cancer screening for high-risk individuals doesn't have enough evidence for benefit over harms to be covered by Medicare, an advisory panel concluded.
The Centers for Medicare and Medicaid national coverage determination panel voted a mean 2.2 on a 5.0-point scale for confidence in that regard.
Key concerns were the high false-positive rate of CT screening, indication creep outside of the intended screening population, inability to assure quality scans with low radiation dose, and consistent interpretation and diagnostic workup in routine practice.
“If we don’t do it right now, it’s a genie that won’t be able to be stuffed back in the bottle,”Peter Bach, MD, MAPP, of Memorial Sloan-Kettering Cancer Center in New York City, who has been a prominent voice of caution in the national discussion, argued at the panel meeting.
Read the complete story here: http://bit.ly/1fBt9ML
Source: Medpage Today
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
